Adalvo announces the addition of Voclosporin 7.9mg Soft Gel Capsules to its portfolio.
Based on the reference brand Lupkynis, Voclosporin is indicated for treating adult patients with Lupus Nephritis (LN).
Voclosporin represents the first FDA-approved oral therapy for patients with active Lupus Nephritis.
In 2023, Lupkynis achieved global sales of $160 million, as reported in the company’s annual report. According to GlobalData, the peak sales forecast for Voclosporin is projected to reach $600 million by 2028.
Including Voclosporin in Adalvo's portfolio aligns with our mission to expand access to high-quality, effective treatments. We are dedicated to bringing differentiated solutions to the market that improve patient outcomes and quality of life.
There are no half-measures at Adalvo – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Partner Up Now